Beneficial effects of CCL8 inhibition at lipopolysaccharide-induced lung injury
Open Access
- 7 November 2022
- Vol. 25 (12) , 105520
Abstract
No abstract availableKeywords
Funding Information
- National Science Foundation (OIA1736150)
- Society for Community Research and Action
This publication has 45 references indexed in Scilit:
- Induction of CCL8/MCP-2 by Mycobacteria through the Activation of TLR2/PI3K/Akt Signaling PathwayPLOS ONE, 2013
- Drug Induced Interstitial Lung DiseaseThe Open Respiratory Medicine Journal, 2012
- An Official American Thoracic Society Workshop Report: Features and Measurements of Experimental Acute Lung Injury in AnimalsAmerican Journal of Respiratory Cell and Molecular Biology, 2011
- Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ TH2 cellsNature Immunology, 2011
- CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasisCytokine & Growth Factor Reviews, 2010
- Synergistic up‐regulation of MCP‐2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti‐tumoral effectsEuropean Journal of Immunology, 2009
- CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host diseaseBlood, 2008
- TNF‐mediated inflammatory diseaseThe Journal of Pathology, 2007
- A randomized controlled trial with an anti‐CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- Manipulation of inflammation in ARDS: achievable goal or distant target?Thorax, 2006